#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

In short

Dr. Gaya Devi, a neurologist and psychiatrist, discusses the evolving understanding of dementia as a spectrum disorder and the exciting new era of personalized treatments. She details her rigorous patient evaluation process, which includes advanced imaging and biomarker testing, to identify the unique pathological drivers in each individual. The conversation covers the role of inflammation, genetic predispositions like APOE4, and sex differences in Alzheimer's. Dr. Devi shares her experience with anti-amyloid drugs, advocating for a cautious, slow titration approach to manage side effects while maximizing benefits. She also touches on vascular and Lewy Body dementias, emphasizing the importance of accurate diagnosis and tailored interventions, including targeted brain exercises and neuromodulation. Dr. Devi concludes with an optimistic outlook, believing that early, personalized treatment can significantly alter the trajectory of cognitive decline.

Key takeaways

• Dementia, particularly Alzheimer's, is a spectrum disorder with varied presentations and underlying pathologies (amyloid, tau, inflammation), requiring a personalized diagnostic and treatment approach.
• Early detection and aggressive management of risk factors, including inflammation (e.g., from viruses or poor oral health) and metabolic dysfunction, are crucial for preventing or slowing cognitive decline.
• Anti-amyloid drugs, while controversial, can clear pathology and offer clinical benefit, especially when administered with a slow titration protocol to mitigate side effects like ARIA, and may be more effective in earlier stages of the disease.
• Women face a higher risk of Alzheimer's, partly due to estrogen loss during menopause, and may benefit from hormone replacement therapy or targeted interventions to support brain health.
• A comprehensive evaluation, including advanced imaging, biomarker testing (blood, CSF), and detailed cognitive assessments, is essential to understand the unique drivers of cognitive impairment in each patient and guide tailored treatment strategies.

Chapters

1. 00:00

   Introduction and Evolution of Dementia Understanding

   Peter introduces Dr. Gaya Devi, a neurologist and psychiatrist specializing in memory disorders. Dr. Devi discusses the evolution of her understanding of dementia, emphasizing it as a spectrum disorder rather than a binary condition, and highlights the exciting new era of personalized treatments and disease-modifying drugs.

2. 03:10

   Defining Dementia and Alzheimer's Pathophysiology

   Dr. Devi defines dementia as an umbrella term for loss of brain connectivity, with Alzheimer's being the most common type, characterized by extracellular amyloid plaques, intracellular tau tangles, and neuroinflammation. She explains the evolving understanding of the order of these pathological events, with inflammation potentially preceding amyloid deposition.

3. 05:30

   Inflammation, Viruses, and Brain Health

   The discussion touches on the role of inflammation in dementia, with Peter noting the focus on managing viruses like HSV and VZV, and the connection between gingival health and dementia. Dr. Devi agrees that neuroinflammation is a key frontier and shares examples of patients whose inflammatory conditions may have protected them from Alzheimer's pathology.

4. 08:50

   Dr. Devi's Evaluation Process for Dementia

   Dr. Devi details her rigorous evaluation process for patients, especially high-functioning individuals, which includes a meticulous history, extensive cognitive testing, electrophysiology, brain blood flow analysis, specialized MRI, amyloid/tau scans, and genetic testing. She emphasizes tailoring the assessment to each patient and avoiding simplistic staging.

5. 14:30

   The 'Name Recall' Phenomenon

   Peter asks about the common experience of struggling to recall names. Dr. Devi explains that names are inorganic bits of information, and the brain is not designed to remember an endless amount of them, reassuring that this is a normal evolutionary trait rather than a sign of cognitive decline.

6. 16:45

   Sex Differences in Alzheimer's Disease

   Dr. Devi discusses the higher prevalence of Alzheimer's in women, attributing it to factors like longer lifespan, the impact of menopause and estrogen loss on brain health, and differences in immunological susceptibility. She notes that women often present differently, with more depression, withdrawal, and language difficulties.

7. 20:40

   Controversy and Use of Anti-Amyloid Drugs

   The conversation shifts to anti-amyloid drugs like Aducanumab, Lecanemab, and Donanemab. Dr. Devi explains the controversy around their approval, particularly Aducanumab, due to modest clinical benefit despite clearing amyloid, and the risk of side effects like ARIA (brain bleeding/swelling). She shares her personalized, slow titration protocol to mitigate these risks.

8. 27:00

   Vascular Dementia and Lewy Body Dementia

   Dr. Devi highlights that Alzheimer's rarely presents in isolation, often co-occurring with vascular brain disease. She discusses the diagnosis and treatment of vascular dementia, emphasizing aggressive management of cardiovascular risk factors. For Lewy Body dementia, she notes the frequent misdiagnosis as Parkinson's and the importance of distinguishing between the two for appropriate treatment.

9. 33:00

   Future of Dementia Care and Personal Beliefs

   Dr. Devi expresses optimism for the future of dementia care, emphasizing the potential of AI for early detection and targeted neuromodulation. She shares her personal belief, contrary to conventional wisdom, that patients with Alzheimer's can get better with personalized treatment, a realization that evolved through her practice and the advent of biomarkers.

Get the next The Peter Attia Drive recap

A short recap of every new episode, by email. Free for up to 5 shows.